A phase i study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer

Journal of Clinical Pharmacology

Volumn 50, Issue 3, 2010, Pages 268-275

  Curtis, Kelly K ^a   Hartney, Jean T ^b   Jewell, Roxanne C ^b   Park, Jung W ^b   Lebowitz, Peter F ^b   Griffin, Pamela P ^a   Borad, Mitesh J ^a   Fitch, Tom R ^a   Northfelt, Donald W ^a  

^a MAYO CLINIC   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Intravenous; Pharmacokinetics; Safety; Topotecan; Weekly

Indexed keywords

TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS CANCER; FATIGUE; HEAD AND NECK CANCER; HUMAN; INFUSION RATE; KIDNEY CANCER; LEUKOPENIA; LIVER CANCER; LUNG NON SMALL CELL CANCER; NAUSEA; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PROSTATE CANCER; RECTUM CANCER; SMALL INTESTINE CANCER; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; FATIGUE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOPENIA; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; THROMBOCYTOPENIA; TOPOTECAN;

EID: 77649208309     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009343699     Document Type: Article

References (30)

1. D?Arap P., Liu LF Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta. 1989 ; 989: 163-177.
2. Kudelka AP, Tresukosol D., Edwards CL, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol. 1996 ; 14: 1552-1557. (Pubitemid 26134213)
3. Creemers GJ, Bolis G., Gore M., et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol. 1996 ; 14: 3056-3061.
4. Rowinsky EK, Grochow LB, Hendricks CB, et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol. 1992 ; 10: 647-656.
5. Wall JG, Burris HA III, Von Hoff DD, et al. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anticancer Drugs. 1992 ; 3: 337-345.
6. van Warmerdam LJ, ten Bokkel Huinink WW, Rodenhuis S., et al. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion. J Clin Oncol. 1995 ; 13: 1768-1776.
7. Herzog TJ, Powell MA, Rader JS, et al. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. Gynecol Oncol. 2006 ; 103: 637-641.
8. Hochster H., Wadler S., Runowicz C., et al. Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 1999 ; 17: 2553-2561.
9. Haas NB, LaCreta FP, Walczak J., et al. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res. 1994 ; 54: 1220-1226.
10. Homesley HD, Hall DJ, Martin DA, et al. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol. 2001 ; 83: 394-399.
11. Levy T., Inbar M., Menczer J., et al. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol Oncol. 2004 ; 95: 686-690.
12. O?Mally DM, Azodi M., Makkenchery A., et al. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2005 ; 98: 242-248.
13. Bhoola SM, Coleman RL, Herzog T., et al. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecol Oncol. 2004 ; 95: 564-569.
14. Morris R., Alvarez RD, Andrews S., et al. Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers. Gynecol Oncol. 2008 ; 109: 346-352.
15. Verweij J., Lund B., Beijnen J., et al. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol. 1993 ; 4: 673-678.
16. van Warmerdam LJ, Verweij J., Schellens JH, et al. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother Pharmacol. 1995 ; 35: 237-245.
17. Kuppens IE, Witteveen EO, Jewell RC, et al. A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin Cancer Res. 2007 ; 13: 3276-3285.
18. Kruijtzer CMF, Beijnen JH, Rosing H., et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol. 2002 ; 20: 2943-2950.
19. Kantarjian HM, Beran M., Ellis A., et al. Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood. 1993 ; 81: 1146-1151.
20. Saltz L., Sirott M., Young C., et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst. 1993 ; 18: 1499-1507. (Pubitemid 23269185)
21. Pratt CB, Stewart C., Santana VM, et al. Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol. 1994 ; 12: 539-543.
22. Hochster H., Liebes L., Speyer J., et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol. 1994 ; 12: 553-559.
23. Gordon AN, Tonda M., Sun S., et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004 ; 95: 1-8.
24. ten Bokkel Huinink W., Lane SR, Ross GA ; International Topotecan Study Group. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol. 2004 ; 15: 100-103.
25. ten Bokkel Huinink W., Gore M., Carmichael J., et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997 ; 15: 2183-2193. (Pubitemid 27251118)
26. Meier W., du Bois A., Reuss A., et al. Topotecan versus treosulphan in early recurrent ovarian cancer after primary platinum/ paclitaxel chemotherapy: a prospective randomized phase III trial of the AGO Ovarian Cancer Study Group [abstract 005]. Int J Gynecol Cancer. 2004 ; 14 (suppl 1). 2.
27. Fung-Kee-Fung M., Oliver T., Elit L., et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007 ; 14: 195-208.
28. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology v.1.2008: Ovarian Cancer. Available at http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp. Accessed October 29, 2008.
29. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology v.1.2008: Small Cell Lung Cancer. Available at http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp. Accessed October 29, 2008.
30. Ackermann S., Beckmann MW, Thiel F., et al. Topotecan in cervical cancer. Int J Gynecol Cancer. 2007 ; 17: 1215-1223.